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Abstract
Background: Mammalian cardiac myocytes withdraw from the cell cycle during post-natal development, resulting in a non-
proliferating, fully differentiated adult phenotype that is unable to repair damage to the myocardium, such as occurs
following a myocardial infarction. We and others previously have shown that forced expression of certain cell cycle
molecules in adult cardiac myocytes can promote cell cycle progression and division in these cells. The mitotic serine/
threonine kinase, Polo-like kinase-1 (Plk1), is known to phosphorylate and activate a number of mitotic targets, including
Cdc2/Cyclin B1, and to promote cell division.
Principal Findings: The mammalian Plk family are all differentially regulated during the development of rat cardiac
myocytes, with Plk1 showing the most dramatic decrease in both mRNA, protein and activity in the adult. We determined
the potential of Plk1 to induce cell cycle progression and division in cultured rat cardiac myocytes. A persistent and
progressive loss of Plk1 expression was observed during myocyte development that correlated with the withdrawal of adult
rat cardiac myocytes from the cell cycle. Interestingly, when Plk1 was over-expressed in cardiac myocytes by adenovirus
infection, it was not able to promote cell cycle progression, as determined by cell number and percent binucleation.
Conclusions: We conclude that, in contrast to Cdc2/Cyclin B1 over-expression, the forced expression of Plk1 in adult cardiac
myocytes is not sufficient to induce cell division and myocardial repair.
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Introduction
Mammalian cardiac myocytes lose the ability to divide shortly
after birth, [1–4], differentiating into cell cycle arrested binucleated
cells. Subsequent growth of the myocardium is achieved through an
increase in myocyte cell size, known as hypertrophy. Following
myocardial injury, cardiac myocytes are lost from the damaged area
and replaced by scar tissue. Any loss in cardiac function is
compensated by a physiological hypertrophic response and cardiac
remodeling. Although this process initially helps to maintain cardiac
output, the remodeling process continues and eventually leads to the
development of pathological hypertrophy and heart failure [5–7].
The change in growth potential of cardiac myocytes during cardiac
development and hypertrophy is reflected in the expressions and
activities of certain cell cycle molecules.[8–15] Thus, positive
regulators of the cell cycle machinery, such as the Cdk/cyclin
complexes and the pro-proliferative E2F transcription factors (E2F1-3)
are down regulated, whilst negative regulators, including retinoblas-
toma protein (pRb) and the cyclin-dependent kinase inhibitors
(CDKIs), p21 and p27, are upregulated. As a consequence, the
majority of adult mammalian cardiac myocytes are arrested inG0/G1,
with the remaining cells being present at the G2/M transition[15].
Current strategies aimed at encouraging repair of the heart
focus on the use of stem cells or gene therapy to induce cell
division and differentiation at the site of damage to reduce the size
of the infarct and improve patient outcome.[16,17] In support of
the gene therapy approach, work from our laboratory[12,13,18]
and others (see below) have shown that manipulation of the
cardiac myocyte cell cycle machinery could be a suitable
therapeutic approach for promoting myocardial repair. Alterations
in the expressions of certain cell cycle molecules can increase
cardiac myocyte proliferation in vitro,[18–25] inhibit the induction
of hypertrophy in vitro[12] or increase cardiac myocyte num-
ber[14,24] and promote myocardial repair[25,26] in vivo. These
studies have highlighted a number of potential targets for the
reinitiation of cardiac myocyte cell division, with the aim of
increasing the number of cardiac myocytes and reducing infarct
size to improve patient outcome.
The Polo-like kinases (Plks) are a family of serine/threonine
kinases that exhibit sequence identity in both their N-terminal
catalytic domain and their C-terminal region, which is termed the
polo-box domain (PBD). This C-terminal region contains phospho-
peptide binding motifs[27,28], called ‘polo-boxes’, that are essential
for Plk localization and regulation.[29–32] This family of kinases
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includes the mammalian Plks: Plk1, Plk2 (Snk), Plk3 (Fnk/Prk) and
Plk4 (Sak-a/b); Xenopus laevis Plx1,[33] Schizosaccharomyces pombe
plo1+ and Saccharomyces cerevisiae CDC5 [34–36].
Plk1 is important for mitotic progression (karyokinesis and
cytokinesis); it is involved in the nuclear translocation of cyclin
B1,[37] microtubule dynamics,[38–42] activation of Cdc25C,[42]
inactivation of Wee1[43,44] and Myt1,[45] separation of chro-
mosomes at anaphase and destruction of mitotic proteins through
activation of the anaphase promoting complex/cyclosome (APC/
C).[46,47] Recently, it has been demonstrated that Plk1
contributes to cytokinesis in human cells[48,49] and that inhibition
of Plk1 activity with the highly selective inhibitor, BI
2536,[48,50,51] results in cytokinesis failure and the generation
of binucleated cells. Plk2–4 display varying roles in cell cycle
progression: Plk2 plays a role in centriole duplication;[52] Plk3 is a
non-cycling Plk[53] involved in G2 checkpoint signaling.[54] Plk4
differs from Plk1–3 as it contains a variation of the Plk kinase motif
and has a single polo-box.[55] Plk4 has been shown to localize to
centrioles and, like Plk2, is thought to be important for centriole
duplication. Loss or over expression of Plk4 results in defects in the
centriole cycle and aberrant spindle formation [56–59].
Previously, Plk1 mRNA and protein have been shown to decline
during rat cardiac myocyte development.[60] We have extended
these studies and characterized the expression of the whole family of
mammalian Plks during rat cardiac myocyte development. We
confirmed that the expression and activity of Plk1 in cardiac
myocytes declines during development in accordance with observa-
tions previously reported.[60] Plk2, Plk3 and Plk4 also showed small,
but significant, changes at the mRNA and protein levels during
development. In addition, we have tested the hypothesis that over
expression of Plk1 would reinitiate the cell cycle in G2/M-arrested
cells and increase the number of cardiac myocytes. Adenovirus
constructs were generated to express wild-type Plk1 or a constitu-
tively active Plk1 with the phospho-mimicking T210D mutation.
Despite being able to increase HeLa cell proliferation, we found that
over expression of Plk1 was unable to induce cell cycle progression in
isolated neonatal rat cardiac myocytes at 48 hours, or in adult rat
cardiac myocytes at 24 hours. We found that this most likely due to
the inability of Plk1 to increase the activity of Cdc2/cyclin B1. Based
on these findings, we sought to further characterize the G2/M arrest
originally observed in adult cardiac myocytes with the aim of
determining a more precise description of the G2/M arrest. Using
an immunohistochemical approach, we found no evidence of G2/M
marker expression in the adult myocardium and conclude that this
may be indicative of an earlier arrest.
Materials and Methods
Ethics Statement
Ventricular cardiac myocytes were isolated from wild type
Wistar rats which were housed and maintained in a colony in
accordance with the Local Ethical Review Panel of the University
of Reading and U.K. Home Office guidelines. All experimental
procedures using animals were performed in accordance with the
U.K. Animals (Scientific Procedures) Act, 1986.
Materials
Dual-labeled quantitative PCR probes and oligonucleotides were
synthesized by Sigma-Genosys (Pampisford, U.K.). ABgene Absolute
QPCR Rox Mix (ABgene; Epsom, UK) was used according to the
manufacturer’s instructions. Samples were normalized to either the
ribosomal subunit, 18S, using the 18SQPCR kit (Applied Biosystems,
Warrington, UK) or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) QPCR kit (Applied Biosystems, Warrington, UK).
Samples were amplified on an Applied Biosystems 5700 GeneAmp
QPCR machine. The High-Fidelity PCR system was supplied by
Roche Diagnostics (Lewes, U.K.). Anti-(cyclin B1) (GNS1) and anti-
(CDC2 p34), antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, U.S.A.). Anti-Plk1 monoclonal antibody
cocktail was purchased from Zymed (Invitrogen, Paisley, U.K.). Anti-
Plk2 and Plk4 antibodies were purchased from Bethyl Laboratories
(Montgomery, TX, U.S.A.), and an anti-Fnk/Plk3 antibody was
purchased from BD Biosciences. The anti-tropomyosin (sarcomeric)
antibody (clone CH1) was obtained from Sigma (Poole, U.K.). Anti-
Histone H3 Ser10 antibody was purchased from Millipore (Watford,
U.K.) and anti-Histone H3 Ser28 and Ki67 antibodies were
purchased from Abcam (Cambridge, U.K.) Horseradish-peroxi-
dase-conjugated secondary antibodies were purchased from Dako-
Cytomation (Ely, U.K.) and AlexaFluorH 568 and 488 anti-mouse
IgG secondary antibodies were purchased from Molecular Probes
(Eugene, OR, U.S.A.). Vectashield mounting medium containing
DAPI (49,6-diamidino-2-phenylindole) was purchased from Vector
Laboratories (Orton Southgate, Peterborough, U.K.). Expression
vector pIRES2-EGFP (enhanced green fluorescent protein) was
obtained from BDClontech UK (Basingstoke, U.K.). Quantity OneH
software package was from Bio-Rad (Hemel Hempstead, U.K.). BD
MatrigelTM Matrix (growth factor reduced) was supplied by
Fahrenheit Laboratories (Milton Keynes, U.K.). All other chemicals
and biochemicals were supplied by Sigma.
HeLa Cell Proliferation Assay
HeLa cells (56105) were plated into 6 well dishes and maintained
in DMEM supplemented with 10% FCS for 24 hours prior to
infection. Cells were infected at an MOI of 50 and cell number was
assessed by Coulter Counter at 48 hours post infection. Cells were
washed, trypsinised and resuspended in Isoton II solution (Beckton
Dickinson, Oxford, U.K.) prior to counting.
Cardiomyocyte isolation
Fetal [gestational day 18 (E18)] and neonatal [2- (P2), 3- (P3), 5-
(P5), 7- (P7) and 10- (P10) days old] ventricular cardiomyocytes
were isolated from 30–70 excised ventricles of Wistar rats as
described previously [12,18]. Cells were maintained in either
serum-free (0%) myocyte media (80% DMEM, 20% M199) or
myocyte media supplemented with 5% fetal calf serum (FCS).
Cardiomyocyte-enriched cultures were at least 95% pure, as
determined by anti-tropomyosin staining. Adult ventricular
cardiomyocytes were isolated from the excised hearts of male
Wistar rats (175–200 g) by Langendorff perfusion [10,13] and
maintained in modified M199 media (M199 supplemented with
2 mM creatine, 2 mM carnitine and 5 mM taurine).
Quantitative PCR
Primers and probes were designed using Primer ExpressTM
Software (Applied Biosystems, Warrington, UK) as follows: Plk1 Rat
Plk1 QPCR-Fwd 1121:59- CTCCCGAACCACTGGTTCC-39, Rat
Plk1 QPCR-Rev 1189: 59- CTTAATAAAGGTGTGGAGAACC-
CC-39, Rat Plk1 Probe: 59-TAMRATGCCTGACCGTCCCCGGA-
GAFAM- 39; Plk2 QPCR-Fwd: 59-GTCCTTTCAGTGGGTCAC-
CAA-39 Rat Plk2 QPCR-Rev: 59- GTGTGGTCTGAGAGCTGG-
TATCC-39, Rat Plk2 Probe: 59-TAMRATGGGTCGACTACT-
CCAACAAATACGGCTT-FAM-39; Plk3 QPCR-Fwd: 59-GCCTA-
CGCGGTCAAAGTCA-39, Rat Plk3 QPCR-Rev: 59- TTATGA-
TCTTCTCGCGCTGATG-39, Rat Plk3 Probe: 59-TAMRACCG-
CAGAGTCGCGTCGCCAFAM- 39; QPCRRat Plk4-Fwd: 59- AA-
GCAGAATGAGCGAGAATAG-39, QPCR Rat Plk4-Rev: 59- CC-
TTCCACTGTCACAGCAGAAG- 39, Rat Plk4: 59-TAMRACG-
GCTTTCCCAACACAGACACCAGTACTC-FAM-39.
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Adenovirus-infection studies
Recombinant adenoviruses expressing wild-type (WT) or
constitutively active Plk1 (T210D) or EGFP alone were generated
using the AdEasy System (QBiogene, Carlsbad, USA). For adult
cardiomyocyte infection studies, isolated adult myocytes were
plated in serum-free modified M199 medium (M199 containing
2 mM creatine, 5 mM taurine and 2 mM carnitine) for 1 hr on
MatrigelTM-coated six-well dishes. Adherent adult cardiomyocytes
were washed and then infected at a MOI (multiplicity of infection)
of 50 plaque forming units of each virus per cell in modified M199
medium. Infected cultures were maintained in modified M199
medium for 24 h before analysis. Neonatal cells were transfected
24 hours after isolation. Cells were washed with PBS and infected
in either serum-free M199 media or M199 supplemented with 5%
FCS. Cells were incubated for 48 hours prior to analysis.
Western Blotting
Protein expression levels were determined by SDS-PAGE
analysis as previously described [10,13].
In vitro kinase assays
Cdc2/cyclin B1 immunocomplexes were immunoprecipitated
from 250 mg of protein extracted from infected cultures using anti-
cyclin B1 antibody and kinase activity measured as described
previously [18]. For Plk1 kinase assays, protein lysate was prepared
from infected cell cultures in TBSN lysis buffer (50 mM HEPES
pH 7.4, 150 mM NaCl, 1 mM EGTA, 25 mM b-glycerophos-
phate, 25 mM NaF, 0.5 mM Na3VO4, 10 mM p-nitro phenyl-
phosphate (pNPP), 0.1% Nonidet P-40, 72 mg/ml AEBSF, 10 mg/
ml leupeptin, 5 mg/ml aprotinin). Samples were precleared with
30 ml Protein-G Agarose beads at 0.1 g/ml (Sigma) at 4uC on a
rotating wheel for 1 hour. Plk1 was immunoprecipitated with
1.5 ml monoclonal mouse anti-Plk1 antibody cocktail (Zymed) and
pulled down with 30 ml Protein G-Agarose. Immunoprecipitated
Plk1 was washed twice in TBSN buffer and twice in TDSN
(50 mM Tris pH 7.5, 10 mM MgCl2, 5 mM dithiothreitol (DTT),
2 mM EGTA, 0.5 mM sodium vanadate, 20 mM p-nitrophenyl
phosphate) and incubated with 4 mg casein, 10 mCi AT32P and
10 mM ATP in 25 ml TDSN buffer at 30uC for 30 minutes. The
reaction was terminated by boiling the samples in 1X Laemmli
buffer with 0.2 M dithiothreitol (DTT) for 5 minutes. Samples
were loaded on a 10% polyacrylamide gel and transferred onto
nitrocellulose membrane. Membranes were assessed with a
phosphorimager cassette (Molecular Dynamics) for the desired
time.
Immunocytochemistry
Neonatal cardiomyocytes were cultured in 5% myocyte media
on gelatin-coated glass coverslips for 24 h before infection with
recombinant adenoviruses. Adult cardiomyocytes were plated on
to MatrigelTM-coated chamber slides for 1 hr before infection with
recombinant adenoviruses. Cell monolayers were fixed in 1% (v/v)
formaldehyde in PBS for 10 min at room temperature (21uC),
permeabilised with 0.5% (v/v) Triton X-100 in PBS for 15 min
and blocked in 10% (v/v) normal goat serum/2% (w/v) BSA in
PBS for 30 min. Cardiac myocytes were identified by staining with
cardiac myocyte markers: anti-tropomyosin (sarcomeric) mono-
clonal antibody (clone CH1) was detected with anti-mouse IgG
AlexaFluorH 568 or anti-troponin I was detected with anti-rabbit
IgG AlexaFluorH 488 conjugate. These markers were used to
distinguish cardiomyocytes from non-myocytes. Images were
collected using an Axioskop2 microscope in conjunction with
AxioVision software (Zeiss).
Statistical analysis
All results are presented as means6standard error of the mean
(SEM). Data were analyzed by one-way ANOVA followed by the
appropriate t-test, with P,0.05 considered to be statistically
significant.
Results
Expression and activity of Plk1 declines during rat cardiac
myocyte development
Based upon previous studies showing the downregulation of
positive regulators of cell cycle molecules during cardiac myocyte
development, we hypothesized that the expression of Plk1 would
be downregulated as these cells progressed towards full differen-
tiation. Quantitative PCR analysis revealed a progressive decline
in Plk1 mRNA levels during development (Figure 1A) and this was
also seen at the protein level (Figure 1B). No Plk1 protein was
detected in adult cardiac myocytes. Interestingly, the activity of
Plk1 does not change significantly at P10, compared to P3 levels,
despite a decline in Plk1 expression (Figure 1B–E). These results
suggest that there is a change in the regulation of Plk1 leading to
increased activity at P10 compared to levels in P3 cardiac
myocytes that is independent of protein synthesis.
mRNA and protein levels of Plk2, Plk3 and Plk4 during rat
cardiac myocyte development
Quantitative PCR revealed differential patterns of regulation for
Plk2, Plk3 and Plk4 mRNA during the postnatal developmental
period; all are significantly downregulated in the adult. Plk2
showed very little change from E18 levels throughout postnatal
development (Figure 2A) whereas Plk3 showed a small, but
significant, increase in mRNA levels during the early postnatal
growth phase (P2 and P5) (Figure 2B). Plk4 showed a small,
significant decrease at P2 and is downregulated by ,90% in the
adult compared to E18 levels (Figure 2C). At the protein level,
Plk2, Plk3 and Plk4 are all expressed in the adult (Figures 3A to F),
unlike Plk1, which is not be detected in adult cardiac myocytes
(Figure 1B). Plk2 protein levels showed a considerable degree of
variability between samples (n = 5); protein levels do not appear to
change significantly during development. Plk3 protein expression
also remains unchanged during early postnatal development, but
does appear to be downregulated in the adult heart by ,40%
compared to embryonic day 18 (E18). Plk4 protein levels decrease
as development proceeds, with a significant downregulation at P2
and in the adult (Figure 3E and F).
Based upon the data showed here, Plk1 is the most interesting
candidate for re-initiation of cell cycle in adult cardiac myocytes. No
protein expression or activity is detectable in the adult heart, whereas
Plk2–4 are all expressed, albeit at lower levels, compared to E18.
Adenoviral expression of active Plk1 in both HeLa cells
and cardiac myocytes
Petronczki et al (2007)[48] have shown that inhibition of Plk1 in
HeLa cells released from a metaphase block results in binuclea-
tion. The majority of adult cardiac myocytes are binucleated and
do not express Plk1. We hypothesized that reintroduction of Plk1
into isolated adult rat cardiac myocytes might drive the cells
through a successful round of nuclear and/or cell division, thereby
increasing cell number. Accordingly, we generated adenoviruses
carrying Plk1 in conjunction with an internal ribosomal entry site
(IRES) and EGFP marker. To confirm the ability of the Plk1
construct to induce cell cycle progression in proliferating cells,
HeLa cells were infected with adenovirus containing either EGFP,
Plk1 & Myocardial Regeneration
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wild-type or constitutively active (T210D) Plk1 at a multiplicity of
infection (MOI) of 50 (50 virus particles per cell). Forty eight hours
post infection, we found that over-expression of wild-type (WT)
Plk1 increased the number of HeLa cells by 2365.6% (n= 3,
p = 0.02), compared to the EGFP control (Figure 4A and B).
Constitutively active Plk1 (T210D) also increased HeLa cell
numbers by 2061.5% above the EGFP control. This data shows
that adenovirus-delivered Plk1 was able to induce cell division in
proliferative cells. We then assessed the activity of adenovirus-
delivered Plk1 by in vitro kinase assay in non-proliferating P10
cardiac myocytes: Plk1 kinase activity was increased in both WT
and T210D Plk1 expressing cells (Figure 4C).
Over-expression of catalytically active Plk1 has no effect
on cardiac myocyte binucleation
We next determined the effect of over expressing catalytically
active WT and T210D Plk1 on cardiac myocyte cell binucleation.
Ventricular cardiac myocytes were isolated from P3, P7 and adult
Wistar rat hearts and subjected to adenovirus infection as above;
P7 cardiac myocytes were chosen due to their improved viability
following isolation compared to P10 cells (data not shown). The
effect of EGFP, WT or constitutively active (T210D) Plk1
expression on cardiac myocyte binucleation was assessed by
calculating the number of nuclei per cardiac myocyte. For
uninfected postnatal cells, the number of binucleated cells
increased from ,20% at P3 to ,40% at P7. Adult cardiac
myocytes showed extensive (,90%) binucleation (Figure 5A).
Surprisingly, we found adenovirus-delivered Plk1 did not have a
significant effect on the percentage of binucleated cardiac
myocytes at any stage of development (Figures 5B, C and D).
This was somewhat surprising, especially at P3 where there is still a
capacity for cell division. To determine whether there had been an
effect on cell number but not on binucleation, we performed cell
counts at P3 and found that there was no significant increase in
Figure 1. Plk1 expression and activity declines during rat cardiac myocyte development. Ventricular cardiac myocytes were isolated from
Wistar rat hearts at various stages of development (embryonic day 18 [E18], 2, 5 and 10 days postnatal [P2, P5 and P10] and adult [250 g males]) and
assessed for Plk1 mRNA (A, normalised to GAPDH) and protein (B, normalised to GAPDH) expression and activity (C). D) representative western blot of
Plk1 expression. E) Representative kinase assay and corresponding protein expression (GAPDH was used as a loading control). Data is from three
separate experiments, * p,0.05.
doi:10.1371/journal.pone.0006752.g001
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cardiac myocyte cell number when the cells were incubated in
either serum free media (n = 3, WT p=0.378; T210D p= 0.100)
or media supplemented with 5% FCS (n= 3, WT p=0.277,
T210D p= 0.892) compared to EGFP control (Figure 5E). Cell
counts were performed on permeabilised, fixed samples stained
with cardiac specific markers so rule out increases in cell number
by contaminating cardiac fibroblast cells.
Over-expression of Plk1 does not increase the activity of
Cdc2/cyclin B1 in P3 cardiac myocytes
Whilst over-expression of Plk1 had no effect on binucleation in
adult cardiac myocytes, it was surprising that Plk1 had no effect on
P3 cardiac myocytes at all. P3 cardiac myocytes express the mitotic
regulator Cdc2/cyclin B1[18] and retain a limited proliferative
capacity. Plk1 promotes activation of Cdc2/cyclin B1[37,42] and
inhibits the activity of the Cdc2/cyclin B1 inhibitors, Wee1 and
Myt1[43,45,61]. Therefore, we evaluated the effect of Plk1 over
expression on Cdc2/cyclin B1 activity in P3 rat cardiac myocytes
to determine whether this might explain the lack of cell cycle
progression. Interestingly, the activity of Plk1 increased in cells
infected with both wild-type and constitutively active Plk1
adenovirus, whereas the activity of Cdc2/cyclin B1 in these cells
was unaffected (Figure 6). This data shows that the activation of
Cdc2/cyclin B in differentiating rat cardiac myocytes cannot be
achieved solely by the over expression of Plk1 and highlights the
complexity of cell cycle regulation in cardiac myocytes. This work
shows that careful consideration is required when choosing which
molecules should be selected for these studies. It is clear that the
cell cycle must be manipulated in precisely the right way in order
to elicit cell cycle progression.
Cardiac myocytes do not express G2/M markers
The current study aimed to determine whether Plk1 could be a
potential therapeutic target for the initiation of cardiac repair in
the mammalian heart. This hypothesis was based on previous
studies that have shown that a significant population of adult
cardiac myocytes is G2/M arrested [14,15,62,63]], and that over
expression of the G2/M regulator Cdc2/cyclin B1 is sufficient to
Figure 2. Regulation of Plk2, Plk3 and Plk4 mRNA expression during cardiac myocyte development. Ventricular cardiac myocytes were
isolated from hearts at various stages of development (embryonic day 18 [E18], 2, 5 and 10 days postnatal [P2, P5 and P10] and adult [250 g males])
and assessed for Plk2, Plk3 and Plk4 mRNA (black bars, A, B and C, respectively). Samples were normalised to GAPDH. Each bar chart represents data
from at least 3 separate experiments, * p,0.05.
doi:10.1371/journal.pone.0006752.g002
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Figure 3. Expression of Plk2, Plk3 and Plk4 protein levels are regulated during cardiac myocyte development. Ventricular cardiac
myocytes were isolated from hearts at various stages of development (embryonic day 18 [E18], 2, 5 and 10 days postnatal [P2, P5 and P10] and adult
[250 g males]) and assessed for Plk2, Plk3 and Plk4 protein expression (A, C and E, respectively, black bars). Samples were normalised to GAPDH. Each
bar chart represents data from at least 3 separate experiments, * p,0.05. Representative blots are shown for Plk2 (B), Plk3 ((D) and Plk4 (F).
doi:10.1371/journal.pone.0006752.g003
Plk1 & Myocardial Regeneration
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increase cell number in vitro[18]. Although the data presented here
shows that Plk1 is unable to do this, it does highlight that a more
definitive understanding of the arrest in cardiac myocytes is
necessary in order to successfully identify potential targets for a
gene therapy approach. In order to further characterise the arrest
in cardiac myocytes, and a therefore provide a smaller number of
potential targets, we decided to more precisely define the point
within the G2/M arrest that these cells are arrested in. Four
micrometre sections were taken from E18, P3, P10 and adult
Wistar rat hearts (Figure 6) and assessed for the expression of Ki67
and phosphorylation of histone H3 at serine 10 (Ser10) and at
serine 28 (Ser28).
The proliferation marker, Ki67, is present in all phases of the
cell cycle, increasing from G1 to maximal intensity at the
metaphase-anaphase transition, but is not found in telophase nor
in quiescent, G0, cells[64]. Histone H3 becomes phosphorylated
on Ser10 during late G2 and is important for chromosome
condensation[65–67]. Ser28 is also phosphorylated during mitosis,
and like Ser10 phosphorylation, contributes to chromosome
condensation [68]. However, unlike Ser10, Ser28 is not phos-
phorylated until the onset of mitosis[68] and therefore serves as a
more faithful mitotic marker.
The expression of Ki67 and the phosphorylation of histone H3
at Ser10 and Ser28 declined with age (Figure 7). Very few (Ki67,
0.4960.25%; Ser10, 0.3560.27%; Ser28, 0.2960.15%; n= 3,
mean6SEM) troponin-I-positive adult cardiac myocytes demon-
strated any staining or mitotic figures. Previous studies have
investigated the isolated nuclei of adult cardiac myocytes using
FACS analysis using dual staining for bromodeoxyuridine (BrdU)
and propidium iodide (PI) [14,15]. This type of analysis
determines cell cycle stage by assessing the DNA content of each
event (cell or nucleus) as it passes through the laser. Any event
displaying a double DNA content, such as a post-S phase, mitotic
or binucleated cell, will be classified as a G2/M cell. The lack of
any Ser10 or Ser28 staining or mitotic structures suggests that the
G2/M population originally observed in adult rat cardiac
myocytes most likely represents a population of late S-phase/
early G2-arrested cells, rather cells in late G2/M. This might
explain why Plk1 is unable to induce cell cycle progression while
Cdc2/cyclin B1 can; Cdc2/cyclin B1 reaches its peak activity
before the G2/M transition while Plk1 peaks at metaphase[69].
Discussion
In this study, we have determined the expression of the
mammalian Plk family of serine/threonine protein kinases in the
developing rat cardiac myocyte in an effort to better understand
why adult cardiac myocytes are unable to proliferate and repair
the damaged myocardium, and to potentially identify novel
therapeutic targets that could be manipulated to encourage
myocardial repair.
Developing cardiac myocytes undergo binucleation during
neonatal growth,[70–73] whilst adult cells undergo a G1/S transition
during the process of hypertrophy.[2,74]. Both Plk2 and Plk4 are
Figure 4. Effect of adenovirus-delivered Plk1 on HeLa cell number and Plk1 activity. Plk1 enhanced cell division in HeLa cells at 48 hours
post infection (A and B). The activity of adenovirus-delivered Plk1 was assessed in P10 cardiac myocytes (C).
doi:10.1371/journal.pone.0006752.g004
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required for S-phase progression and the associated centriole
duplication process [52,56–59] and this most likely explains the
presence of these two proteins in the adult cardiac myocyte.
Plk3 was originally identified as an immediate-early response
gene that was upregulated in NIH3T3 cells in response to
FGF.[75] It has been reported that Plk3 has a role in G2
checkpoint signaling [76,77] and is activated following treatment
of cells with 100 mM doxorubicin or H2O2.[54,78] We show here
that at the protein level, the expression of Plk3 does not change
during rat cardiac myocyte development, with levels persisting to
Figure 5. Over expression of Plk1 has no effect on adult cardiac myocyte binucleation. Ventricular cardiac myocytes were isolated and
infected with EGFP, WT or T210D adenovirus and incubated for 48 hours (P3 and P7) or 24 hours (adult) in serum free media or media supplemented
with 5% foetal calf serum (FCS). Cells were fixed and assessed for binucleation. A) Cardiac myocyte binucleation increases with age. Over expression
of Plk1 had no effect on binucleation at P3 (B), P7 (C) or adult (D) stages of development. E) Plk1 over expression does not increase cardiac myocyte
cell number, as determined by the number of troponin I positive cardiac myocytes per image (cells were counted for three separate images for EGFP,
WT and T210D-infected cells from three separate experiments).
doi:10.1371/journal.pone.0006752.g005
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the adult stage. Adult cardiac myocytes are thought to be blocked
in G2/M and it is possible that Plk3 could contribute to the
arrested state of these cells.
The decline in Plk1 mRNA and protein levels and activity
observed during cardiac myocyte development is consistent with
previous studies from our laboratory, and others, examining the
expression of other such positive regulators of the cell cy-
cle[8,11,12,18,21,23–25] and extends the work by Georgescu et
al [60]. To investigate the role of Plk1 in nuclear and cellular
division in rat cardiac myocytes, we over expressed wild type and
constitutively active Plk1 in adult myocytes for 48 hours in the
absence or presence of serum to determine whether Plk1 activity
could induce cell division. Neither the wild type nor the
constitutively active mutant induced any changes in cell cycle
progression, in terms of the percentage of binucleated cells, or cell
number. Surprisingly, we also found that catalytically active Plk1
was unable to increase the activity of endogenous Cdc2/cyclin B1
in P3 cardiac myocytes, suggesting that Plk1 is unable to complete
with the other factors that regulate activity of the Cdc2/cyclin B1
complex. As well as dephosphorylation of Cdc2 at Thr14 and
Tyr15 by Cdc25C, phosphorylation of Thr161 in the catalytic T-
loop by Cdk activating kinase (CAK) is essential for Cdc2/cyclin
B1 activity.[79] It is likely that some of these other factors limit the
activation of endogenous Cdc2/cyclin B1; for example, CAK
phosphorylates Cdc2 at Thr161 [80] and this modification is
required for full activation of the Cdc2/cyclin B1 complex. If Plk1
can only enhance the activity of Cdc2/cyclin B1 that already is
phosphorylated at Thr161, the amount of active Plk1 present
would be irrelevant if CAK is the rate-limiting factor in Cdc2/
cyclin B1 activation. In addition to this, whilst Plk1 has been
reported to inhibit the Cdk inhibitor, Wee1, it has been shown that
an initial Cdk-mediated phosphorylation of Wee1 at Ser121 is
necessary to produce a Plk1 docking site, and that this
phosphorylation event is required for increased Plk1 binding[43].
If the Cdk activity in P3 cardiac myocytes is not sufficient to prime
Wee1 for Plk1 binding, over expression of Plk1 alone will not be
sufficient for Wee1 inhibition and, therefore, an increase in Cdc2/
cyclin B1 activity.
Cdc2/cyclin B1 is involved in some of the early stages of mitosis,
such as the breakdown of the nuclear envelope and chromosome
condensation[81]. Because ectopic Cdc2/cyclin B1 can elicit an
increase in the number of adult cardiac myocytes, whilst Plk1 can
not, it is possible that in the heart these cells are in an early/mid-
G2, rather than in late-G2/M arrest. As such, the introduction of
Plk1 into adult myocytes could be too far downstream of this
arrest, and therefore unable to bypass the other events that are
necessary to occur before mitosis can take place. Based upon the
observations reported here, we sought to characterize the G2/M
arrest in more detail. Previous reports have suggested that a G2/M
arrested population of cardiac myocytes exists in the rat adult
heart.[14,15] To examine this further, we prepared heart sections
and assessed them for any evidence of mitotic arrest by the
phosphorylation of histone H3 on serine 10 or serine 28. Cells
staining positive for cardiac myocyte markers and phosphorylation
of either serine residue declined with age, with virtually no adult
cardiac myocytes staining positive. The expression of the cell cycle
marker, Ki67, was also assessed during rat heart development and
was shown to be absent from the adult heart. This data suggests
that adult cardiac myocytes are not in a state of ‘G2/M’ arrest as
previously reported[15], but that the arrest could be earlier, such
as late S/G2. This raises questions about the involvement of
mechanisms of endoreduplication, rather than mitosis, being
responsible for cell cycle arrest in the adult cardiac myocyte.
Cardiac myocytes are known to increase in terms of ploidy
following myocardial infarction[82]. It is possible that the increase
in ploidy seen in the myocardium surrounding an infarct[82] is an
attempt at cell division that is inhibited by the absence of Cdk or
Plk1 activity at G2, leading to rounds of DNA synthesis in the
absence of cell division. This may partially explain the presence of
the previously reported population of G2/M nuclei;[15] these
nuclei may in fact be the product of replication origin re-licensing
and endoreduplication rather than an aborted mitosis.
Figure 6. Exogenous Plk1 does not increase the activity of
endogenous Cdc2/cyclin B1 in isolated P3 rat cardiac myo-
cytes. Ventricular cardiac myocytes were isolated from Wistar rats 3
days after birth (P3). Adenovirus expressing EGFP, WT or T210D was
used to infect cells for 48 hours. Cells were harvested and assessed for
Plk1 and Cdc2/cyclin B1 kinase activity. Plk1 activity was assessed by its
ability to phosphorylate casein (A, upper panel). Cdc2/cyclin B1 activity
was assessed by phosphorylation of histone H3 (A, lower panel). B)
Representative western blot of Plk1 over expression in P3 cardiac
myocytes infected with EGFP, WT or T210D adenovirus. GAPDH was
used to verify equal loading.
doi:10.1371/journal.pone.0006752.g006
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Figure 7. Loss of cell cycle markers from the developing rat heart correlates with the decline in proliferative capacity of the cardiac
myocyte. Hearts were excised from embryonic (E18), neonatal (P3 and P10), and adult Wistar rats, frozen in embedding media and sections were cut
at 4 mm. Left hand panel (A, C and E) show bar chart summaries (n = 3, SEM, * p,0.05) while the right hand panel (B, D and F) show representative
sections for each cell cycle marker at each age group. (B) Cardiac myocytes were identified by the cardiac myocyte-specific marker, tropomyosin (red),
histone H3 phosphorylated at Ser10 (green), and nuclei were stained with DAPI (blue). (D) Cardiac myocytes were identified by the cardiac myocyte-
specific marker, tropomyosin (red), histone H3 phosphorylated at Ser28 (green), and nuclei were stained with DAPI (blue). (F) Cardiac myocytes were
stained with the cardiac myocyte specific marker, troponin I, Ki67 staining is red and DNA was stained with DAPI (blue).
doi:10.1371/journal.pone.0006752.g007
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It is vital that this arrest is characterised in more detail;
identifying the precise site of the arrest is important if we are to
successfully find new targets for re-initiating cardiac myocyte
division post-infarct or during heart failure.
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